Cite

HARVARD Citation

    Appelbaum, J. et al. (n.d.). 100 Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML. Journal for immunotherapy of cancer. p. A63. [Online]. 
  
Back to record